Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Kai Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0384-4754; OpenAlex author ID A5013717377, A5138133911. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 14

  1. Activatable nanoflytrap achieves synergistic "Capture-Block-Regulate" therapy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12951-026-04420-3↗
  2. Serum High-Density Lipoprotein Cholesterol Concentrations in Pancreatic Ductal Adenocarcinoma and Its Association With Histological Grade in a Chinese Populati… Co-author DOI 10.1177/10732748251316602↗
  3. Multimodal Imaging-Guided Photoimmunotherapy of Pancreatic Cancer by Organosilica Nanomedicine. Co-author DOI 10.1002/adhm.202302195↗
  4. Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer. Co-author DOI 10.1016/j.medj.2024.02.012↗
  5. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Co-author DOI 10.1002/cam4.5296↗
  6. Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma. First author DOI 10.1177/20552076231179007↗
  7. Exploring the key genetic association between chronic pancreatitis and pancreatic ductal adenocarcinoma through integrated bioinformatics. Co-author DOI 10.3389/fgene.2023.1115660↗
  8. Erratum: Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer [Corrigendum]. Co-author DOI 10.2147/ijn.s361728↗
  9. Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer. Co-author DOI 10.2147/ijn.s335588↗
  10. Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.744667↗
  11. Diagnostic accuracy of unenhanced CT texture analysis to differentiate mass-forming pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-020-02506-6↗
  12. Computed Tomography-Based Radiomics Signature for the Preoperative Differentiation of Pancreatic Adenosquamous Carcinoma From Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.01618↗
  13. Differentiation of chronic mass-forming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. Co-author DOI 10.2147/cmar.s217033↗
  14. A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy. Co-author DOI 10.2217/nnm-2019-0063↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuai Ren · 13 shared papers, 2019–2025 · strength 2.08
  2. Zhongqiu Wang · 11 shared papers, 2019–2024 · strength 1.61
  3. Yingying Cao · 6 shared papers, 2020–2025 · strength 1.04
  4. Lina Song · 5 shared papers, 2019–2024 · strength 0.80
  5. Rui Zhao · 5 shared papers, 2020–2023 · strength 0.71
  6. Zipeng Lu · 3 shared papers, 2021–2023 · strength 0.48
  7. Wenli Qiu · 3 shared papers, 2019–2024 · strength 0.41
  8. Yuan Li · 2 shared papers, 2023 · strength 0.36
  9. Huifeng Zhang · 2 shared papers, 2019–2024 · strength 0.30
  10. Zhongqiu Wang · 1 shared paper, 2026 · strength 0.29
  11. Yuan Li · 1 shared paper, 2025 · strength 0.27
  12. Rong Chen · 2 shared papers, 2020 · strength 0.23
  13. Xiao Chen · 2 shared papers, 2019–2021 · strength 0.23
  14. Sean M. Ronnekleiv‐Kelly · 1 shared paper, 2024 · strength 0.20
  15. Patrick Beard Schwartz · 1 shared paper, 2024 · strength 0.20
  16. Zhaoting Li · 1 shared paper, 2024 · strength 0.20
  17. Yu Chen · 1 shared paper, 2024 · strength 0.20
  18. Quanyin Hu · 1 shared paper, 2024 · strength 0.20
  19. Jian He · 1 shared paper, 2023 · strength 0.17
  20. Kai Zhang · 1 shared paper, 2023 · strength 0.17
  21. Donghui Li · 1 shared paper, 2023 · strength 0.17
  22. Tao Li · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.